Progenics Pharmaceuticals, Inc. (PGNX) Announces The Completion Of Enrollment Of Chemotherapy Naive Cohort In Phase 2 Trial Of PSMA ADC
4/24/2014 8:54:58 AM
TARRYTOWN, N.Y., April 24, 2014 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) an oncology company focused on the development of innovative approaches to targeting and treating prostate cancer, announced today the completion of enrollment in the chemotherapy naïve cohort in its Phase II trial of PSMA ADC. This cohort of 36 chemotherapy naïve prostate cancer patients, all of whom progressed on hormonal therapies, was added to the Phase II trial following positive response to PSMA ADC in patients in the chemotherapy experienced setting.
Help employers find you! Check out all the jobs and post your resume.
comments powered by